Nalaganje...
Defining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases
Brain metastases (BMs) are the most common cause of malignant central nervous system (CNS) tumors in adults. In the recent past, patients with BMs were excluded from clinical trials, but now, with the advent of new biological and immunological drugs, their inclusion is more common. In the last era r...
Shranjeno v:
| izdano v: | Transl Lung Cancer Res |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2016
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5233872/ https://ncbi.nlm.nih.gov/pubmed/28149758 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2016.11.02 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|